TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00699868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Description: Sampling of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Description: Sampling of blood
Study: NCT01503554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Social Worker and Pharmacist Program
Description: Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Intervention: Usual Care
Description: Patient receives usual care upon discharge from the hospital.
Study: NCT00573664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: single oral dose of 600mg gabapentin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Single dose
Study: NCT05573152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: All previously selected patients will be under passive warming by means of blankets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing
Description: All previously selected patients will be under active air flow warming device at 43 Celsius
Study: NCT02071537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered day 1 of each 21 day cycle for 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
Study: NCT02190188

Intervention type: DEVICE
Group type: OTHER
Intervention: Wedge Insole 5mm

Intervention type: DEVICE
Group type: OTHER
Intervention: Knee Brace
Study: NCT06001671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109
Description: BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109
Description: BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109
Description: BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd
Study: NCT02281708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine plus cisplatin
Description: Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks
Study: NCT02518334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: 28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
Study: NCT02737358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: NAC or matched placebo will be given to study participants for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
Study: NCT03210740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM001 Cream, 7.5%
Description: Active Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Placeo
Study: NCT02600117

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg, oral, once a day
Study: NCT04882371

Intervention type: DRUG
Intervention: Chemotherapy
Description: Neoadjuvant Chemotherapy for Breast Cancer

Intervention type: DRUG
Intervention: Chemotherapy
Description: Neoadjuvant Chemotherapy for Breast Cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron emission tomography - Copmputer Tomography (PET-CT)
Description: Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
Study: NCT02204501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 528 mg QD
Description: Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
Study: NCT02688218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
Study: NCT03676491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Music intervention
Study: NCT03413592

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study: NCT00531453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, and thalidomide
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, thalidomide, and cyclophosphamide
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.
Study: NCT00942760

Intervention type: DEVICE
Intervention: 3T MRI
Description: The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
Study: NCT00848939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
Study: NCT03413592

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study: NCT03498677

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: presentation order
Description: section presentation one

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alternative presentation order
Description: section presentation two
Study: NCT03312738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
Study: NCT00546403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Adjunctive treatment with titrated dose of modafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjunctive treatment with placebo
Study: NCT01394978

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard surgical techniques including staples and sutures.
Study: NCT02940301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02691715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial saline plus curettage
Study: NCT01394978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGEL Pleural Air Leak Sealant with standard surgical closure
Description: ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGEL Pleural Air Leak Sealant without standard surgical closure
Description: ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
Study: NCT02691715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial curettage
Study: NCT00183430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are taken orally twice per day at 10 am and bedtime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: All participants will undergo psychotherapy during medication treatment period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy
Description: All participants will undergo psychotherapy during medication treatment period.
Study: NCT06002893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesfytol NG®) supplement
Description: General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement
Study: NCT00658788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray 0.05%
Description: clobetasol propionate spray, 0.05%, applied topically twice daily
Study: NCT02543840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs plus External Facilitation
Description: Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Materials
Description: Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
Study: NCT03774108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG
Description: 8 weeks tratment with oral metformin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks tratment with oral placebo
Study: NCT01116557

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency Ablation procedure
Description: Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation procedure
Description: Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
Study: NCT03028246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 System
Description: Focused ultrasound
Study: NCT00658788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol ointment
Description: calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
Study: NCT01891201

Intervention type: DRUG
Intervention: Oxytocin
Description: Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
Study: NCT02661919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emfit mattress sensor
Description: Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
Study: NCT02793388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supervised primaquine treatment
Description: Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised primaquine treatment
Description: Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
Study: NCT05476302

Intervention type: OTHER
Intervention: Cognitive digital treatment
Description: The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
Study: NCT02577822

Intervention type: DEVICE
Group type: OTHER
Intervention: Taperloc standard length stem

Intervention type: DEVICE
Group type: OTHER
Intervention: Taperloc short length stem
Study: NCT02627092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper linen exposure
Description: Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
Study: NCT00000167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Laser Treatment
Description: Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
Study: NCT01410968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells
Description: Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
Study: NCT01687907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Study: NCT03796702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deileostomy
Description: Deileostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deileostomy
Description: Deileostomy
Study: NCT02432196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Medical Device
Description: It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
Study: NCT04224337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + doxorubicin + ifosfamide
Description: Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
Study: NCT01244477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CPT-C
Description: Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
Study: NCT01863771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
Study: NCT03367429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
Study: NCT00247234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Therapy
Description: group based schema therapy
Study: NCT03438877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive dosage of PD
Description: Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular dosage of PD
Description: Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
Study: NCT00247234

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard psychiatric out-patient care
Study: NCT01112319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elf care
Description: elfcare device
Study: NCT03248492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Study: NCT01112319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: regular physiotherapy treatment